ChartMill assigns a Buy % Consensus number of 77% to ALBO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-02-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-01-11 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-01-11 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2023-01-11 | Jefferies | Downgrade | Buy -> Hold |
| 2023-01-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-01-09 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-10-13 | HC Wainwright & Co. | Maintains | Buy |
| 2022-10-12 | Baird | Maintains | Outperform |
| 2022-09-08 | Guggenheim | Initiate | Buy |
| 2022-08-16 | Wedbush | Maintains | Outperform |
| 2022-08-16 | Baird | Maintains | Outperform |
| 2022-08-16 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | Baird | Maintains | Outperform |
| 2021-11-05 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-16 | Wedbush | Maintains | Outperform |
| 2021-07-21 | Wedbush | Maintains | Outperform |
| 2021-07-21 | HC Wainwright & Co. | Maintains | Buy |
| 2021-03-01 | Piper Sandler | Maintains | Overweight |
13 analysts have analysed ALBO and the average price target is 42.84 USD. This implies a price decrease of -2.97% is expected in the next year compared to the current price of 44.15.
The consensus rating for ALBIREO PHARMA INC (ALBO) is 76.9231 / 100 . This indicates that analysts generally have a positive outlook on the stock.